Biocon Launches Aflibercept Biosimilar Yesafili in the US

Biocon announced the commercial launch of Yesafili (aflibercept-jbvf) in the United States, expanding the availability of an interchangeable biosimilar to Eylea (aflibercept) 2 mg for the treatment of retinal vascular diseases. The FDA approved Yesafili in May 2024 and granted the product interchangeable designation, allowing pharmacy-level substitution for the reference product.

A Proposed Medicare Policy Would Tie Our Hands in the Fight Against Glaucoma

Chuck Williamson Jr

Glaucoma Today

As an ophthalmic practice administrator, I see every day what it takes to deliver the interventional glaucoma care necessary to preserve sight. It is not a simple cookie-cutter approach. A proposed Medicare policy would make it harder still, replacing physician judgment with a rigid, one-size-fits-all sequence that ignores how differently this disease behaves from patient to patient. What the LCDs Would Restrict Five Medicare Administrative Contractors (MACs) have similar Local Coverage Determinations (LCDs) in the proposal stage and available for comment through July 4. At issue is coverage of the intracameral travoprost implant (iDose TR, Glaukos). If the LCDs become finalized, Medicare would not cover the procedural pharmaceutical unless patients first fail both a trial of selective laser trabeculoplasty (SLT) and two topical medications. The LCD would also bar physicians from placing the implant during a MIGS procedure, whether that MIGS procedure is performed alone or in combination with cataract surgery. If finalized, the LCDs would take decision-making out of the hands of physicians and replace individualized judgment with a fixed treatment sequence applied to every patient. One Treatment Pathway Does Not Fit Every Patient Glaucoma is a heterogeneous disease. It presents and progresses differently in each patient, and physicians need a full range of options to treat each case individually.

Featured Podcasts

Ophthalmology off the Grid

Open. Outspoken. It's Ophthalmology off the Grid—an honest look at controversial topics in the field.

View Feed

New Retina Radio

New Retina Radio is a place to hear stories about retina that are told nowhere else.

View Feed

Eyewire News: The Podcast

Get the latest information and breaking news in the ophthalmic field.

View Feed

Eyewire News

08.03.2026

Biocon Launches Aflibercept Biosimilar Yesafili in the US

08.04.2026

University of Iowa Research Underpins First-in-Human UK Study of Gene Therapy Targeting Rare IRD

08.04.2026

Swedish Study Finds Small Absolute Risk of NAION Among GLP-1 Receptor Agonist Users

08.04.2026

Opus Genetics Completes Enrollment in Phase 3 Trial of Gene Therapy for Inherited Retinal Disease

08.03.2026

MDConsult AI Launches Pre-Consultation Platform for Cataract and Refractive Practices

EyewireTV

07.29.2026

The Latest EyewireTV

Outlook Therapeutics CEO Discusses FDA Approval of Lytenava for Wet AMD

Roche Receives Positive Opinion from EMA Committee for Wet AMD Treatment Susvimo

Glaukos Completes Enrollment in Pivotal Trial Evaluating Preserflo MicroShunt for POAG

Stocks

Cataract

Netarsudil Joins the Glaucoma Toolbox

Integrating MIGS Without Disrupting Efficiency

Elara 900: Reinventing the Clinical Workhorse

Interventional Glaucoma: A Collaborative Care Model for the Future of Glaucoma Management

MIGS Device Selection in Practice

Seeing More of the Cornea

08.03.2026

MDConsult AI Launches Pre-Consultation Platform for Cataract and Refractive Practices

07.24.2026

Théa, Unither Pharmaceuticals Partner on Dedicated Ophthalmic Manufacturing Facility in France

07.21.2026

Pediatric Cataract Surgery May Alter Coordination of Ocular Growth, International Study Finds

07.21.2026

Fundamental XR, Orbis Report Early Success of VR Ophthalmic Training Program Across Africa

Refractive

IJC Recap: Treating Inflammatory Dry Eye, an Emerging Option for Normal Tension Glaucoma, and the Role of Yag Laser Vitreolysis for Vitreous Floaters

It Is Not Good to Be Shallow

Netarsudil Joins the Glaucoma Toolbox

Integrating MIGS Without Disrupting Efficiency

PRIMA Retinal Implant Launched in EU

Interventional Glaucoma: A Collaborative Care Model for the Future of Glaucoma Management

08.03.2026

MDConsult AI Launches Pre-Consultation Platform for Cataract and Refractive Practices

07.23.2026

iVeena Reports FDA Alignment on Phase 2 Development Plan for Pediatric Myopia Candidate IVMED-85

07.21.2026

Fundamental XR, Orbis Report Early Success of VR Ophthalmic Training Program Across Africa

07.17.2026

Moorfields and University College London Launch CADMUS Anterior Segment Imaging Dataset

Stay Updated

Follow Eyewire News

Retina

Fluocinolone Implant

Iatrogenic Breaks During Macular Hole Surgery

Retina Then and Now: July/August Spotlight

Therapies for IRDs: Moving Beyond Single-Gene Solutions

Genetic Testing in the Retina Practice

Dense Cataract

08.04.2026

University of Iowa Research Underpins First-in-Human UK Study of Gene Therapy Targeting Rare IRD

08.04.2026

Swedish Study Finds Small Absolute Risk of NAION Among GLP-1 Receptor Agonist Users

08.04.2026

Opus Genetics Completes Enrollment in Phase 3 Trial of Gene Therapy for Inherited Retinal Disease

08.03.2026

Biocon Launches Aflibercept Biosimilar Yesafili in the US

Glaucoma

A Proposed Medicare Policy Would Tie Our Hands in the Fight Against Glaucoma

Paul Implant

Alloflo and the Future of the Supraciliary Space

Hemorrhagic Choroidals After Combined Phaco-Trabeculectomy

Canaloplasty and ECP

Preserflo Microshunt

07.27.2026

Glaukos Completes Enrollment in US Pivotal Study of Preserflo MicroShunt for POAG

07.24.2026

Théa, Unither Pharmaceuticals Partner on Dedicated Ophthalmic Manufacturing Facility in France

07.21.2026

Fundamental XR, Orbis Report Early Success of VR Ophthalmic Training Program Across Africa

07.17.2026

Glaucoma UK Launches Nationwide Patient Survey Targeting 10,000 Responses